U.S. Markets closed
  • S&P Futures

    4,115.75
    -7.25 (-0.18%)
     
  • Dow Futures

    33,930.00
    -66.00 (-0.19%)
     
  • Nasdaq Futures

    13,201.25
    -10.75 (-0.08%)
     
  • Russell 2000 Futures

    2,206.00
    -1.90 (-0.09%)
     
  • Crude Oil

    64.98
    -0.51 (-0.78%)
     
  • Gold

    1,870.50
    +2.50 (+0.13%)
     
  • Silver

    28.27
    -0.06 (-0.20%)
     
  • EUR/USD

    1.2235
    +0.0009 (+0.0734%)
     
  • 10-Yr Bond

    1.6420
    +0.0020 (+0.12%)
     
  • Vix

    21.34
    +1.62 (+8.22%)
     
  • GBP/USD

    1.4198
    +0.0011 (+0.0795%)
     
  • USD/JPY

    108.9400
    +0.0500 (+0.0459%)
     
  • BTC-USD

    42,747.23
    -1,448.34 (-3.28%)
     
  • CMC Crypto 200

    1,200.32
    -52.82 (-4.22%)
     
  • FTSE 100

    7,034.24
    +1.39 (+0.02%)
     
  • Nikkei 225

    28,037.40
    -369.44 (-1.30%)
     

Top Analyst Reports for Facebook, Adobe & Novo Nordisk

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Mark Vickery
·6 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Thursday, April 1, 2021

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Adobe (ADBE), and Novo Nordisk (NVO). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Facebook shares have outperformed the S&P 500 over the past year (+86.2% vs. +59.4%). The Zacks analyst believes that Facebook is benefiting from steady user growth across all regions, particularly Asia-Pacific.

Increased engagement for its products like Instagram, WhatsApp and Messenger is a major growth driver. Strong advertising revenues were driven by a strong holiday shopping season for retail that benefited from the ongoing shift to online commerce.

Facebook expects year-over-year growth rates in total revenues to remain stable or modestly accelerate on a sequential basis in the first and second quarters of 2021. However, increasing regulatory headwinds in the EU and other countries is a concern.

(You can read the full research report on Facebook here >>>)

Adobe’s shares have lost 0.8% over the last six months against the Zacks Software industry’s gain of 9.9%. The Zacks analyst believes that Adobe is benefiting from strong demand for its creative products.

The company’s Creative Cloud, Document Cloud and Adobe Experience Cloud products are driving the top-line growth. Further, rising subscription revenues and solid momentum across the mobile apps are major positives.

Additionally, growth in emerging markets, robust online video creation demand and improving average revenue per user are tailwinds. However, lower end-market demand and exposure to Europe remain overhangs. High acquisition expenses do not bode well for its margin expansion.

(You can read the full research report on Adobe here >>>)

Shares of Novo Nordisk have lost 5.6% in the past three months against the Zacks Large Cap Pharmaceuticals industry’s loss of 0.1%. The Zacks analyst believes that Victoza, Ozempic, Xultophy and Saxenda have been helping the company maintain momentum.

Label expansion of existing drugs is likely to further boost sales. Novo Nordisk beat both sales and earnings estimates for the fourth quarter of 2020.

In 2021, the company will continue its focus on commercial execution, while conducting more late-stage clinical studies than ever to meet the needs of the people living with diabetes and other serious chronic diseases. However, lower realized prices in the United States, loss of exclusivity for products in hormone replacement therapy and intensifying competition will affect sales.

(You can read the full research report on Novo Nordisk here >>>)

Other noteworthy reports we are featuring today include PetroChina (PTR), Edwards Lifesciences (EW) and Teladoc Health (TDOC).

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.

Click here for the 4 trades >>

Mark Vickery
Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Today's Must Read

Expanding User Base, Instagram Strength Aid Facebook (FB)

Adobe (ADBE) Rides on Growing Adoption of Cloud Applications

Novo Nordisk's (NVO) Diabetes Drugs Aid Growth Amid Rivalry

Featured Reports

Higher Production, Lower Costs to Aid PetroChina (PTR)

The Zacks analyst believes that the rise in oil and gas production and a tight leash on lifting costs will aid the company's exploration and production segment results.

Robust SAPIEN 3 Ultra Uptake Aids Edwards Lifesciences (EW)

The Zacks analyst is upbeat about the strong adoption of Edwards Lifesciences' SAPIEN 3 Ultra amid the pandemic.

Teladoc (TDOC) Gains From Rise in Revenues, Telehealth Visit

Per the Zacks analyst, Teladoc's revenues have been benefiting from a rise in membership and patient visits.

Acquisitions to Buoy CNH Industrial (CNHI) Amid Chip Crunch

CNH Industrial's buyout of Potenza Technology is likely to boost its e-mobility prospects. However, a global deficit in semiconductor supply may hurt the firm's near-term sales, per the Zacks analyst.

Burlington Stores' (BURL) 2.0 & Store-Growth Plan Bode Well

Per the Zacks analyst, Burlington Stores' 2.0 initiative, which aims at improving the execution of the off-price model, looks encouraging. The company's long-term store-growth target is also on track.

Abiomed (ABMD) Gains From Solid Prospects in Impella Platform

Abiomed has been gaining from its flagship Impella platform. The Zacks analyst is however, concerned about pricing pressure and tough competition.

Vail Resorts (MTN) Banks on Strategic Investments, Traffic Dismal

Per the Zacks analyst, Vail Resorts is likely to benefit from investments in project expansion, technology program and marketing initiatives.

New Upgrades

Valero (VLO) to Gain From Higher Distillate Fuel Demand

The allowed sulfur content in marine fuel has declined massively, leading to higher distillate fuel demand. Valero, being a producer of the fuel, will capitalize on this, expects the Zacks analyst.

Disruptive Pricing, Growing Customer Base Aid Ubiquiti (UI)

Per the Zacks analyst, higher direct-to-consumer sales via webstores and disruptive pricing mechanism on the back of an accretive clientele base drive Ubiquiti's growth.

Envestnet (ENV) Rides on Recurring Revenue Generation Capacity

The Zacks analyst is impressed with Envestnet's business model which ensures solid asset-based and subscription-based recurring revenue generation capacity.

New Downgrades

Customer Concentration & Competition Hurt Skyworks (SWKS)

Per the Zacks analyst, significant pricing pressure amid stiff competition from peers like Qorvo in radio frequency market, and high customer concentration risks remain major headwinds for Skyworks.

ZTO Express (ZTO) Takes a Hit From Escalated SG&A Expenses

The Zacks analyst is worried about the steep operating expenses due to high selling, general and administrative (SG&A) costs. Decline in gross profit is concerning too.

Weak BSD Unit Weighs on The ODP Corporation's (ODP) Sales

Per the Zacks analyst, pandemic-led headwinds across the CompuCom, BSD and Retail units hurt The ODP Corporation sales in fourth quarter. Such headwinds are likely to persist in first-half of 2021.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Teladoc Health, Inc. (TDOC) : Free Stock Analysis Report
 
PetroChina Company Limited (PTR) : Free Stock Analysis Report
 
Novo Nordisk AS (NVO) : Free Stock Analysis Report
 
Facebook, Inc. (FB) : Free Stock Analysis Report
 
Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report
 
Adobe Inc. (ADBE) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research